Did Cipla Launch India's First Non-Antibiotic Drug for Recurrent UTI?
Click to start listening
Synopsis
Cipla has taken a significant step in combating recurrent UTIs by launching HUENA, a non-antibiotic treatment. This innovative drug not only aims to prevent infections but also seeks to reduce the reliance on antibiotics, addressing the pressing issue of antimicrobial resistance. This launch could change the landscape of UTI treatment in India.
Key Takeaways
- HUENA is a non-antibiotic option for UTI prevention.
- Methenamine Hippurate offers cost-effective treatment.
- It addresses the challenge of Antimicrobial Resistance (AMR).
- Women are the primary demographic affected by UTIs.
- Cipla is leading innovation in the pharmaceutical industry.
New Delhi, Sep 5 (NationPress) Cipla announced on Friday the introduction of Methenamine Hippurate, a revolutionary non-antibiotic solution aimed at individuals battling recurrent Urinary Tract Infections (UTIs), marketed under the name HUENA.
In India, UTIs rank as the second most prevalent reason for antibiotic prescriptions, with incidence rates having doubled over the past three decades.
Women are particularly vulnerable to UTIs, accounting for 15% of all antibiotic prescriptions, as stated by the company.
Cipla highlighted that Methenamine Hippurate provides a viable, non-antibiotic method for UTI prevention by specifically targeting bacteria in the bladder and urinary tract.
Research indicates it is as effective as extended, low-dose antibiotic therapy for preventing UTIs, while being more affordable and eliminating the risk of antibiotic resistance.
Achin Gupta, Global Chief Operating Officer at Cipla, remarked, "The launch of HUENA demonstrates our unwavering commitment to antimicrobial stewardship and addressing the escalating threat of Anti-Microbial Resistance (AMR). We are confident that this innovation will significantly enhance patient outcomes and decrease dependence on antibiotics, contributing to a healthier future for everyone."
As the first to introduce this treatment in India, Cipla marks a significant milestone in the fight against AMR.
Jaideep Gogtay, Global Chief Medical Officer at Cipla, emphasized, "We acknowledge the pressing need for innovative strategies to tackle the mounting challenge of AMR. This groundbreaking launch offers patients a non-antibiotic option that aids in preventing urinary tract infections without exacerbating antimicrobial resistance."
Last year, the Indian regulatory authority, the Central Drugs Standard Control Organisation (CDSCO), granted Cipla permission to exclusively market and distribute inhaled insulin within the country.
The insulin, known as Afrezza, developed by MannKind Corporation, assists adults with diabetes mellitus in managing their blood sugar levels more effectively.
Unlike traditional injectable insulins, Afrezza is a rapid-acting insulin administered via inhalation, quickly dissolving in the lungs when inhaled and entering the bloodstream efficiently at meal initiation.
Cipla, a global pharmaceutical leader, operates in 74 markets worldwide.
Point of View
Cipla's launch of a non-antibiotic UTI treatment is a pivotal development. This reflects a growing awareness of the need to address antimicrobial resistance while providing effective healthcare solutions. The introduction of HUENA could significantly impact patient care in India, aligning with global health priorities.
NationPress
05/09/2025
Frequently Asked Questions
What is HUENA?
HUENA is Cipla's newly launched non-antibiotic drug, Methenamine Hippurate, designed to prevent recurrent urinary tract infections.
How does Methenamine Hippurate work?
Methenamine Hippurate targets bacteria in the bladder and urinary tract, providing an effective alternative to traditional antibiotic treatments.
What are the benefits of using HUENA?
The benefits include lower costs, effectiveness comparable to low-dose antibiotics, and a reduced risk of developing antibiotic resistance.
Who is more susceptible to UTIs?
Women are particularly more susceptible to UTIs, accounting for a significant portion of antibiotic prescriptions.
Why is antimicrobial resistance a concern?
Antimicrobial resistance is a critical public health issue, as it can lead to treatment failures and increased healthcare costs.
